Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast
Maike Sonnenberg1, Heiko van der Kuip*1, Silke Haubeiß1, Peter Fritz2, Werner Schroth1, Godehard Friedel3, Wolfgang Simon4, Thomas E Mürdter1 and Walter E Aulitzky5

Address: 1Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology and University of Tuebingen, Auerbachstr. 112, 70376 Stuttgart, Germany, 2Department of Diagnostic Medicine, Pathology, Robert Bosch Hospital, Auerbachstr. 110 70376 Stuttgart, Germany, 3Klinik Schillerhöhe, Department of Thoracic Surgery, Grifingen, Germany, 4Department of Gynecology, Robert Bosch Hospital, Auerbachstr 110, 70376 Stuttgart, Germany and 52nd Department of Internal Medicine, Oncology and Hematology, Robert Bosch Hospital, Auerbachstr. 110, 70376 Stuttgart, Germany

Email: Maike Sonnenberg - maike.sonnenberg@ikp-stuttgart.de; Heiko van der Kuip* - heiko.van-der-kuip@ikp-stuttgart.de; Silke Haubeiß - silke.haubeiss@ikp-stuttgart.de; Peter Fritz - peter.fritz@rbk.de; Werner Schroth - werner.schroth@ikp-stuttgart.de; Godehard Friedel - friedel@klinik-schillerhoehe.de; Wolfgang Simon - wolfgang.simon@rbk.de; Thomas E Mürdter - thomas.muerdter@ikp-stuttgart.de; Walter E Aulitzky - walter.aulitzky@rbk.de

* Corresponding author

Published: 11 December 2008
BMC Cancer 2008, 8:364 doi:10.1186/1471-2407-8-364
Received: 15 September 2008
Accepted: 11 December 2008
This article is available from: http://www.biomedcentral.com/1471-2407/8/364
© 2008 Sonnenberg et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Carcinoma-associated fibroblasts (CAFs) can promote carcinogenesis and tumor progression. Only limited data on the response of CAFs to chemotherapy and their potential impact on therapy outcome are available. This study was undertaken to analyze the influence of chemotherapy on carcinoma-associated fibroblasts (CAFs) in vitro and in vivo.

Methods: The in vivo response of stromal cells to chemotherapy was investigated in 22 neoadjuvant treated breast tumors on tissue sections before and after chemotherapy. Response to chemotherapy was analyzed in vitro in primary cultures of isolated CAFs from 28 human lung and 9 breast cancer tissues. The response was correlated to Mdm2, ERCC1 and TP53 polymorphisms and TP53 mutation status. Additionally, the cytotoxic effects were evaluated in an ex vivo experiment using cultured tissue slices from 16 lung and 17 breast cancer specimens.

Results: Nine of 22 tumors showed a therapy-dependent reduction of stromal activity. Pathological response of tumor or stroma cells did not correlate with clinical response. Isolated CAFs showed little sensitivity to paclitaxel. In contrast, sensitivity of CAFs to cisplatinum was highly variable with a GI50 ranging from 2.8 to 29.0 μM which is comparable to the range observed in tumor cell lines. No somatic TP53 mutation was detected in any of the 28 CAFs from lung cancer tissue. In addition, response to cisplatinum was not significantly associated with the genotype of TP53 nor Mdm2 and ERCC1 polymorphisms. However, we observed a non-significant trend towards decreased sensitivity in the presence of TP53 variant genotype. In contrast to the results obtained in isolated cell culture, in tissue slice culture breast cancer CAFs responded to paclitaxel within their microenvironment in the majority of cases (9/14). The opposite was observed in lung cancer tissues: only few CAFs were sensitive to cisplatinum within their microenvironment (2/15) whereas a higher proportion responded to cisplatinum in isolated culture.

Conclusion: Similar to cancer cells, CAF response to chemotherapy is highly variable. Beside significant individual/intrinsic differences the sensitivity of CAFs seems to depend also on the cancer type as well as the microenvironment.
Background
Carcinomas are complex tissues in which cancer cells interact with their surrounding stromal compartment composed of fibroblasts, infiltrating immune cells, vascular network, and extracellular matrix (ECM) molecules. Cancer cells actively influence their adjacent stroma by producing stroma-modulating growth factors such as platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), interleukins, and tumor growth factor beta (TGF-beta) [1,2]. Once activated, tumor fibroblasts (also termed "carcinoma-associated fibroblasts", CAFs) differ from normal fibroblasts [1] and exhibit a distinct gene expression pattern [3]. Various studies have shown that CAFs express a range of growth factors and extracellular matrix remodeling enzymes that modulate proliferation and invasion of tumor cells and tumor angiogenesis [4-7]. In xenograft models it has been demonstrated that CAFs are much more competent in promoting tumor growth than normal fibroblasts [7]. Importantly, these tumor-promoting properties of CAFs appear to be partially independent of the presence of tumor cells and are maintained in vitro even in the absence of the epithelial cells [7,8]. Both genetic and epigenetic alterations underlying this stable tumor supporting phenotype of CAFs have been suggested [9-12].

The functional activity of CAFs appears to be an important determinant for the clinical behavior of tumors. Chang et al. analyzed expression profiles of serum-activated fibroblasts as models for wound healing fibroblasts and compared them with profiles obtained from different tumors [13]. They identified gene expression patterns similar to that of activated fibroblasts within the gene expression signature of tumors. This "wound healing signature" was predictive for poor overall survival and increased risk of metastasis in breast, lung, and gastric cancers [13,14]. The importance of the functional state of the stromal cell compartment was further supported by a recent work published by Finak et al. [15]. They analyzed the expression profiles of microdissection-purified tumor stroma from 51 primary breast tumors and identified a stroma cell signature as an independent prognostic factor predicting clinical outcome more precisely than signatures from whole tissue [15].

In view of these central roles of CAFs for the biology of cancer it seems likely that CAFs are also important for the survival of tumor cells following treatment with DNA damaging agents. Stromal fibroblasts can influence chemosensitivity of tumor cells indirectly by producing and activating extracellular matrix (ECM) molecules. This activated ECM confers chemoresistance by integrin-mediated adhesion to fibronectin [16,17]. Only limited data on the response of CAFs to chemotherapy and their potential impact on therapy outcome are available. Using a xenograft prostate tumor model, El Hilali et al. demonstrated a chemotherapy induced loss of overall tumor mass without reduction of the total number of tumor cells [18]. In addition, co-culture experiments and Xenograft models demonstrated that the efficacy of chemotherapy-induced cell cycle arrest or senescence in stromal fibroblasts is critical for the sensitivity of the tumor compartment [19]. These observations support the view that the response of stromal cells to toxic stress contributes to resistance or sensitivity of the tumor to chemotherapy and might contribute to clinical outcome. We therefore investigated short-term effects of chemotherapy on tumor stroma ex vivo in primary tissues derived from newly diagnosed breast cancer and lung cancer specimens and in isolated CAFs from breast and lung.

Methods
Patients
The database of the Robert Bosch Hospital was reviewed to select women with invasive breast carcinomas referred between 2004 and 2006. Sections for 22 patients were available both from pre-treatment biopsies and post-treatment surgery specimens. Patients' characteristics are given in additional file 1. They received neoadjuvant chemotherapy regimens (as also described in additional file 1) followed by surgery. Pathologic diagnosis as well as tumor and stromal cell grading were performed on a tumor tissue sample obtained by a core needle biopsy before treatment and from the same tumor after surgery. Paraffin-embedded tissue sections (3 μm) were stained with hematoxylin and eosin (H&E).

For isolation of primary cancer associated fibroblasts (CAFs) and tissue slice preparation, fresh material from primary breast and lung tumors were obtained from patients newly diagnosed for breast cancer at the Robert Bosch Hospital (n = 17 for tissue culture and n = 9 for culture of isolated CAFs) and for lung cancer at the Klinik Schillerhöhe (n = 16 for tissue culture and n = 28 for CAF culture) immediately after resection. The investigation was approved by the local ethics committee (project number 396/2005V) and informed consent was obtained from the patients.

Tissue slice preparation and culture
Tissue slice preparation and culture was performed as described previously [20]. For breast cancer tissue cultivation, we used Mammary Epithelial Cell Growth Medium (PromoCell, Heidelberg, Germany). Tissue slices from lung cancer were cultivated in Airway Epithelial Cell Medium (PromoCell, Heidelberg, Germany). Treatment with paclitaxel started 24 hours after preparation of slices for additional 72 hours. After treatment, slices were fixed...
in buffered formalin and embedded in paraffin for further investigation by immunohistochemistry.

**Isolation, cultivation, and characterization of carcinoma-associated fibroblasts (CAFs)**

Tumor tissue was enzymatically digested using a Tissue Disaggregation Buffer (120 mM NaCl, 5.6 mM Glucose, 2.5 mM MgCl₂ × 6H₂O, 5.4 mM KCl, 1 mM NaH₂PO₄, 20 mM HEPES, pH 7.2) supplemented with collagenase (167 U/ml), DNase (250 U/ml) and protease (0.25 mg/ml) for 90 min at 37°C. The disaggregated tissue was filtered through a 70 μm cell strainer (BD Falcon) and the flow-through was seeded in cell culture flasks. The outgrowing fibroblasts were cultivated with RPMI1640 medium supplemented with 20% FCS.

We analyzed CAFs isolated from 16 breast and lung cancer tissue specimens for fibroblast activation protein (FAP) and epithelial specific antigen (ESA) expression. Fibroblasts in the tumor stroma synthesize FAP, a type II transmembrane protein that functions as a serine protease. FAP is expressed in more than 90% of stromal fibroblasts associated with colon, breast, and lung carcinomas [21]. The expression of FAP and ESA was investigated in CAFs from 16 breast and lung cancers using a FAP antibody (FAP-scFv36) or ESA antibody (biomeda, Plovdiv, Bulgaria) by FACS analysis (data not shown). We further performed karyotype analysis with the first 4 CAFs (data not shown). To evaluate 50% growth inhibition values (GI50), we examined cell viability using MTT assays. For this, 5,000 cells were plated in 96-well plates and treated with different concentrations of paclitaxel for 48 hr. The results are shown in Figure 1. For karyotype analysis, we used a tumor cell line panel consisting of 22 cell lines from lung carcinoma, breast carcinoma, ovarian carcinoma, AML, and CML.

Genotyping of **TP53-Arg72Pro** and **ERCC1-118C/T** in CAFs from lung cancer tissue specimens was performed by direct sequencing. Mutation analysis of TP53 was done by sequencing the complete TP53 cDNA. We isolated RNA from frozen cell pellets using the RNAsasy Kit (Qiagen, Hilden, Germany). RNA was reverse transcribed using the RevertAid™ H Minus First Strand cDNA Synthesis Kit from Fermentas (St. Leon-Rot, Germany). The following Primers were used for cDNA amplification (sense: cgcggagtcgagggtag; antisense: ccacaccaaaaccagcgc) and sequencing (primer 1: cacactgagtgagcttag; primer 2: ccacaccaaaaccagcgc). For genotyping of **ERCC1** polymorphism, we isolated DNA from frozen pellets using the DNasy Blood & Tissue Kit from Qiagen (Hilden, Germany) and performed a PCR with the following primer pair: sense: cctcagacctacgccgata, antisense: gcctggttcgtcataggg.

SNP analysis of **Mdm2-309T/G** was done with a PCR-RFLP-based technique using PCR primers: sense: cgccggagtcgagggtag and antisense: actagcgccggtt cacac. The PCR product was digested with 5 units of MspAII (New England Biolabs, Frankfurt a.M., Germany) at 37°C for 16 hr and electrophoresed on a 2% agarose gel stained with ethidium bromide (a representative example is shown in additional file 2).

**Pathologic examination and immunohistochemistry**

Both, tumor and stromal cell response to neoadjuvant treatment was analyzed by comparing H&E stained tissue sections from corresponding samples before and after chemotherapy. We evaluated the regression grade of the tumor compartment according to Sinn et al. (grade 0: no effect, grade 1: resorption and tumor sclerosis, grade 2: minimally focally invasive residues of 5 mm or smaller, grade 3: only non-invasive tumor residues, grade 4: no viable tumor cell detectable [22]). Tumors with regression grades 2, 3, or 4 were defined as tumors with pathological response. To estimate the response of the stromal compartment to chemotherapy, we established a grading system consisting of 4 grading types (representative examples for the grading types are shown in additional file 3). Grade 0 represents tumors with less than 10 fibrocytes per high-power field characterized by small, spindle-shaped nuclei. This grading type corresponds to complete inactive stroma with the lowest cellular density in the stromal area. Grade 1 was defined as mostly inactive stroma with more than 10 fibrocytes per high-power-field and 1–3 vesicular cells (fibroblasts or endothelial cells with enlarged vesicular nuclei). Grade 2 is characterized by intermediate reactive stroma with more than 10 fibrocytes and 3–10 vesicular cells per high-power-field. Tumors with the highest cellular density in stromal area were classified as grade 3 (more than 10 fibrocytes and more than 10 vesicular cells per high-power-field). Stromal response was defined as a change from grade 2 or 3 to grade 0 or 1.

Clinical assessment of chemotherapy was done by comparing tumor size before and after therapy. This included both sonography and MRT. A clinical partial response (cPR) was defined as a >50% reduction in the product of the two longest perpendicular tumor dimensions. Patients not achieving a 50% reduction were considered to be clinical non responders (cNR). Patients without any residual tumor were defined as clinical complete responder (cCR).

**KI67** (anti-human KI67 Antigen, Clone MIB-1, 1:50, Dako) staining was performed using the Dako Envision Kit on a DakoCytomation Autostainer (both DakoCytomation) according to the manufacturer's manual. TUNEL staining was done in compliance to the manufacturer's manual (ApopTag® Kit S7100, Chemicon, Göttingen, Germany). Immunohistochemical assessment was performed...
Cytotoxic chemotherapy effects on isolated CAFs in vitro

We analyzed the acute effects of paclitaxel and cisplatinum on isolated CAFs from primary tumors to evaluate whether CAFs are a direct target of cytotoxic chemotherapy. We isolated CAFs from 9 breast and 28 lung cancer specimens and cultivated them ex vivo for up to 10 passages. All CAFs tested were shown to be positive for FAP and negative for the epithelial specific ESA antigen (not shown) indicating that the isolated fibroblasts were highly homogenous with minimal contamination of other cell types. None of the CAFs investigated for karyotype showed any detectable loss or gain of chromosomal material (not shown).

Notably, CAFs from lung cancer turned out to grow faster than CAFs isolated from breast tumors (not shown). All CAFs exhibited constant proliferation rates for at least 10 passages (not shown). CAFs were treated with increasing dosages of cisplatinum and paclitaxel for 48 hours (see materials and methods) with cell viability analyzed by means of MTT assay. We compared the 50% growth inhibition (GI50) values from these CAFs to those observed in 22 tumor cell lines. Both CAFs from breast and lung cancer specimens showed a significantly lower sensitivity to paclitaxel than the tumor cell line panel (Fig. 2, left panel). In contrast, the sensitivity to cisplatinum in CAFs was highly variable. CAFs isolated from breast carcinomas were significantly less sensitive than CAFs from lung cancer specimens (GI50 = 22.6 ± 6.8 μM for breast vs. GI50 = 11.4 ± 6.7 μM for lung). The variability of the response of lung CAFs to cisplatinum was comparable to that observed in the cancer cell line panel (GI50 = 13.3 ± 8.7 μM; Fig. 2, right panel). Importantly, the sensitivity to chemotherapeutic drugs did not change significantly when tested in early and late passages (not shown).

TP53 somatic mutations and analysis of Mdm2, ERCC1, and TP53 polymorphisms

The p53 tumor suppressor protein is a central player in the cellular reaction to genotoxic stress [23]. A high frequency of somatic mutations in the TP53 gene has been reported in the stromal compartment of breast cancer [11,24]. As we observed a highly variable sensitivity to the DNA damaging agent cisplatinum, we investigated if this variability selectively observed in CAFs from lung cancer is due to genetic changes in genes coding for regulators of DNA damage response. We therefore performed mutation analysis in primary cultured CAFs from lung cancer tissue specimens. No somatic exon mutation was detected in any of the 28 CAFs from lung (not shown).

The single nucleotide polymorphisms (SNPs) TP53-Arg72Pro, Mdm2-309T/G, and ERCC1-118C/T have been implicated in the clinical response to cisplatinum [25,26]. We therefore tested whether these polymorphisms explain the variable sensitivity to cisplatinum observed in CAFs from lung cancer. As shown in figure 3 (left panel) and additional file 4, the TP53 Arg/Pro G>C showed a non-sig...
Stromal cells are target of neoadjuvant chemotherapy in vivo. (a) Representative H&E stained sections from corresponding breast cancer samples before (left panel) and after (right panel) chemotherapy. (b) Clinical response and pathological response of stromal cells (upper panel) and tumor cells (lower panel). Before chemotherapy and before surgery, the two longest perpendicular diameters of the tumor were measured either by MRT or sonography. The product of these diameters was used as a measure of tumor size. Partial clinical response (cPR) was defined as reduction of tumor size of more than 50%; tumors with a reduction of less than 50% or induction of size were defined as non responders (cNR). Tumors with pathological stroma response (characterized by a reduction from stromal grade 2 or 3 to grade 0 or 1; upper panel) and tumors characterized by pathological tumor cell response (tumors with regression grade 2, 3, or 4; lower panel) are displayed as black columns.
significant trend towards decreased sensitivity in the presence of the variant genotype and neither the Mdm2 nor the ERCCI polymorphisms were associated with sensitivity to cisplatinum in these cells (Fig. 3, middle and right panel; additional file 4).

Impact of cytotoxic chemotherapy on proliferation and cell death of stromal cells within tumor tissue in vitro

To evaluate if the sensitivity of CAFs is also determined by the tumor microenvironment, we performed ex vivo experiments with tissues from 17 patients with newly diagnosed breast carcinoma and 16 lung cancer patients.

Tissue slices obtained from breast cancer specimens were incubated with or without paclitaxel and analyzed for proliferation and cell death both in stromal and tumor cells using KI67 and TUNEL immunohistochemistry (representative examples are given in Fig. 4a for KI67 (left panel) and for TUNEL (right panel)). Paclitaxel-induced induction of TUNEL positive cells and reduction of KI67 positive cells was observed both in the tumor and stromal cell compartments. Most of the cases showed a reduction in their KI67 index of more than 10% both in their tumor and stromal cells following paclitaxel treatment. Moreover, an increase of TUNEL positive cells of more than 20% was observed in 7 of 14 cases both in tumor and stromal cells. Reduction of both proliferation and increase of cell death was correlated in tumor and stromal cells following paclitaxel treatment (Fig. 4b; \( P = 0.015 \) and \( P < 0.001 \), respectively).

Tissue slices from lung carcinomas were incubated with or without cisplatinum. Figure 5a shows representative examples of tumors with (left panel) or without (right panel) Cisplatin.
(page number not for citation purposes)
Figure 4 (see legend on next page)
Orimo et al. demonstrated that isolated fibroblasts from tumors maintain their CAF specific phenotype and their capability to proliferate over at least 10 passages in vitro even if epithelial carcinoma cells are not continuously present [7]. In line with this, the CAFs used in the present experiments exhibited a constant proliferation rate over ~10 passages (data not shown). All investigated CAFs were found to be resistant to paclitaxel when compared to a panel of 22 well established cancer cell lines. The CAFs from breast cancer were also mostly resistant to cisplatinum. Only 1 out of 6 tested CAFs from breast cancer showed an intermediate response to this agent. In line with these results, Hawsawi et al. found only 1 of 10 CAFs from breast cancer to be sensitive to cisplatinum [30]. In contrast, we found a remarkable variability of response to cisplatinum in CAFs isolated from lung carcinoma specimens. The GI50 concentrations of cisplatinum ranging from 2.8 to 28 μM were comparable to those obtained in the tumor cell line panel (3.3 to 30.6 μM). Altogether, we conclude that: (1) CAFs respond differently to cisplatinum and paclitaxel; (2) the response of CAFs to cisplatinum shows variability similar to different tumor cell lines; and, (3) CAFs from different organs differ in their response.

Potential causes for the variable response of different CAFs to cisplatinum may be mutations and/or polymorphisms affecting genes involved in DNA damage response mechanisms such as the p53 pathway. Evidence for possible alterations in p53 pathway in CAFs has been provided by several recently published studies. Hawsawi et al. demonstrated that irradiation-induced levels of p53 and p21 are diminished in CAFs when compared to fibroblasts from normal tissues [30]. In addition, several retrospective studies using paraffin-embedded material as source for DNA have reported a high frequency of functional TP53 mutations in the microdissected stromal compartment derived from various carcinomas such as breast, ovarian and colon [11,24,31,32]. We did not find any evidence for somatic TP53 mutations in the CAFs isolated from 28 lung carcinoma patients included in our study. These results indicate that the presence of TP53 mutations in CAFs is limited to certain tumor entities such as breast and colon whereas CAFs from other entities such as lung remain wild type TP53. This would imply that the reaction of CAFs to cytotoxic agents and their influence on therapy response are fundamentally different in different organs. However, since many of the studies reporting on high frequencies of somatic mutations in stromal cells have relied on formalin fixed and paraffin embedded material, it can not be ruled out that the identified mutations may be a reflection of methodological limitations. The latter hypothesis is supported by recently published studies by Allinen et al. [3] and Qui et al. [33]. Qui et al. investigated isolated CAFs and frozen tissues and showed that somatic mutations in CAFs from breast and ovarian carcinomas are extremely rare [33]. Allinen et al. separated myofibroblasts and epithelial tumor cells from fresh breast tumor tissues and found no genetic alterations in myofibroblasts whereas numerous chromosomal gains and losses were detected in the epithelial fractions [3].

We further examined if the variable sensitivity to cisplatinum observed in CAFs from lung cancer could be attributed to functional polymorphisms in genes critical for cellular response to cisplatinum such as TP53, ERCC1, and Mdm2. It has been shown that cells with the TP53 Arg/Arg genotype induce apoptosis significantly better than with Pro/Pro genotype [34,35]. The ERCC1 Codon 118 polymorphism is associated with different mRNA levels and high levels have been associated with a shorter overall survival for colon carcinoma patients treated with platinum-based chemotherapy [36]. Various studies have shown that the G-allele of the polymorphism Mdm2-309T/G in the promoter of the Mdm2 gene is associated with high levels of Mdm2 protein and attenuation of the p53 DNA damage response induced by chemotherapeutic agents [37]. Our data show that none of these polymorphisms is significantly correlated with sensitivity to cisplatinum in CAFs from lung cancer. However, we observed a non-significant trend towards decreased sensitivity in the presence of the TP53 variant genotype which may be one mechanism contributing to the variable response to cisplatinum in CAFs from lung. Due to the
**Figure 5**

**Effect of cytotoxic chemotherapy on stroma and tumor cells in tissues from lung cancer patients.** Tumor tissue slices from 16 patients with primary lung cancer were incubated with or without cisplatinum for 72 hours, then fixed in formalin and analyzed for proliferation and cell death using Ki67 and TUNEL immunohistochemistry. (a) Representative examples of Ki67 and TUNEL stained sections from tissues with cellular response (left panel) and non-response (right panel). Scale bar, 50 μm. (b) Percentage of Ki67 (left histograms) and TUNEL (right histograms) positive cells of both the tumor (upper panel) and the stromal compartment (middle panel) was assessed using a ×40 objective. Three to 7 randomly selected fields were examined for each section. The correlation of tumor and stromal response to cisplatinum regarding changes in proliferation and cell death is shown in the lower panels of the figure. Response to cisplatinum was defined as a reduction of Ki67 positive cells by more than 10% or induction of TUNEL positive cells by more than 20%.
limited number of CAFs included in our study, a final conclusion of potential relevant effects of these polymorphisms on the sensitivity to cytotoxic drugs can not be drawn.

Despite the observation that isolated CAFs retain their cancer promoting phenotype in vitro [7], they may behave differently with respect to DNA damage response within the tumor tissue. There is growing evidence that the cellular environment has an important influence on cellular viability. Cell-cell and cell-matrix interactions responsible for this impact have been studied extensively in 2D and 3D in vitro culture models [38-40], in spheroid models [41,42] and in co-culture experiments using tumor cell lines and fibroblasts [43]. However, these model systems have some limitations since cell-cell and cell-matrix interactions are extremely complex and specific for each individual tumor in vivo [44]. Therefore, we have used a tissue slice culture system which allows the examination of short term effects of chemotherapy on CAFs within their natural environment of the tumor tissue [20]. In tissue cultures from breast carcinomas, paclitaxel-related death of the stromal cell compartment was observed showing an increase of up to 70% apoptotic cells within 72 hours. An interesting finding is that this short term exposure to paclitaxel led to a parallel reaction of both tumor and stromal cells in tissue culture experiments whereas isolated cultured CAFs from breast tumors turned out to be resistant to paclitaxel. These results indicate that within sensitive cancer tissues paclitaxel is highly efficient for compromising the tumor cell compartment and consecutively affecting stroma cells. Within tissue culture, survival of CAFs may be more dependent on supportive factors provided by the individual tumor environment. In contrast, optimized single cell culture conditions for isolated fibroblasts may protect the cells in a more artificial manner. The central role of the microenvironment for response of CAFs to cytotoxic drugs is also demonstrated by our results obtained with lung cancer tissues. In lung cancer, CAFs behave significantly different in cell versus tissue culture. The Ki67 positive fraction of CAFs in tissues was extremely low whereas isolated CAFs showed a constantly high proliferation. Accordingly, CAFs in tissue turned out to be much less sensitive to cisplatinum when compared to the isolated CAFs. These observations indicate that, in addition to intrinsic factors, the microenvironment determines the sensitivity of CAFs to cytotoxic therapy.

Conclusion
In conclusion, our in vivo and in vitro data indicate that stromal reaction is an integral component of tumor response to cytotoxic chemotherapy. Both intrinsic and extrinsic mechanisms influence the variable responses of the stromal compartment to cytotoxic agents. The importance of this variability on the clinical outcome of the carcinoma should be the focus of further investigations.

Abbreviations
(CAFs): Carcinoma-associated fibroblasts; (GI): growth inhibition; (ECM): extracellular matrix; (FCS): fetal calf serum; (FAP): fibroblast activation protein; (ESA): epithelial specific antigen; (H&E): Haematoxylin & Eosin; (μM): micro molar; (PCR): polymerase chain reaction; (RFLP): Restriction Fragment Length Polymorphism; (cCR): clinical complete responders; (cNR): clinical non responders; (cPR): clinical partial responders; (MRT): magnetic resonance tomography; (SNP): single nucleotide polymorphism; (TUNEL): TdT-mediated dUTP-biotin nick end labeling.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
MS, HvDK, TEM, and WEA designed the study and have been involved in drafting the manuscript. GF and WoS prepared and provided the tumor biological samples. PF and WoS reviewed the patient’s histories. MS, SH, and PF participated in the immunohistochemistry studies. WeS and MS performed the genotyping. WeS, TEM, and WEA performed the statistical analysis. All authors discussed and approved the manuscript.

Additional material

Additional file 1
Patients’ characteristics. Table showing patients’ characteristics, received neoadjuvant chemotherapy regimens, and response neoadjuvant chemotherapy.
Click here for file [http://www.biomedcentral.com/content/supplementary/1471-2407-8-364-S1.doc]

Additional file 2
PCR/RFLP analysis of the Mdm2-309T/G polymorphism. Representative PCR/RFLP patterns for the different Mdm2 genotypes: T/T homozygous uncleaved by MspA1I (lanes 1, 4, 5); heterozygous cleaved by MspA1I yielding two bands (lanes 3, 6, 7); G/G homozygous completely cleaved by MspA1I (lanes 2, 8, 9).
Click here for file [http://www.biomedcentral.com/content/supplementary/1471-2407-8-364-S2.pdf]
Acknowledgements
We are grateful to Prof. German Ort and Elisabeth Lüttingen for providing patients' data and to Prof. Klaus Pfizenmaier for his collaboration in analyzing the isolated CAFs in this study. This work was supported by a research grant (O2A and O2B) from the Robert Bosch Foundation, Stuttgart, Germany. We are grateful to Don McClellan for critical reading of the manuscript.

References
1. De Wever O, Mareel M: Role of tissue stroma in cancer cell invasion. J Pathol 2003, 200:429-447.
2. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JL, West AB: Myofibroblasts. I. Paracrine cells important in health and disease. Am J Pathol 1999, 271:C1-9.
3. Allinen M, Beroukhim R, Cai L, Beroukhim R, Brennen C, Lahti-Domenici J, Huang K, Zhang L, Xu Y, Weber F, Caldes T, Mutter GL, Platzer P, Eng C: Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med 2007, 357:2543-2551.
4. Tlsty TD, Hein PW: Know thy neighbor: stromal cells can con-

Additional file 3
Effect of neoadjuvant chemotherapy on stromal and tumor compartment in vivo. Tumor and stromal cell response to neoadjuvant treatment was analyzed by comparing H&E stained sections from corresponding samples before and after chemotherapy. Tumor cell response was evaluated following the classification of Sinn et al. (22). Tumor stroma types were classified in 4 grading groups. Representative H&E stained slides for each type are shown (upper panel: 400×; lower panel: 1000×). Grade 0 represents tumors with less than 10 fibrocytes per high-power-field characterized by small, spindle-shaped nuclei. This grading type corresponds to complete inactive stroma with the lowest cellular density in the stromal area. Grade 1 was defined as mostly inactive stroma with more than 10 fibrocytes per high-power-field and 1–3 vesicular cells (fibroblasts or endothelial cells with enlarged vesicular nuclei). Grade 2 is characterized by intermediate reactive stroma with more than 10 fibrocytes and 3–10 vesicular cells/high-power-field. Tumors with the highest cellular density in stromal area were classified as grade 3 (more than 10 fibrocytes and more than 10 vesicular cells per high-power-field).

Click here for file [http://www.biomedcentral.com/content/supplementary/1471-2407-8-364-S3.pdf]

Additional file 4
CAF cell strains from lung carcinomas. Table showing the G50 values for cisplatinum and the polymorphisms ERCC1-118C/T, and ERCC1C1-118G/T in CAF cell strains from lung carcinomas.

Click here for file [http://www.biomedcentral.com/content/supplementary/1471-2407-8-364-S4.doc]

Page 12 of 13 (page number not for citation purposes)
the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 2002, 95:681-695.

29. McCluggage WG, Lyness RW, Atkinson RJ, Dobbs SP, Harley I, McClelland HR, Price JH: Morphological effects of chemotherapy on ovarian carcinoma. J Clin Pathol 2002, 55:27-31.

30. Hawaswi NM, Ghebeh H, Hendrayani SF, Tulbah A, Al-Eid M, Al-Taweigen T, Ajarin D, Aliays A, Dermime S, Abousselah A: Breast carcinoma-associated fibroblasts and their counterparts display neoplastic-specific changes. Cancer Res 2008, 68:2717-2725.

31. Moinfar F, Man YG, Arnould L, Bratthauer GL, Ratschek M, Tavassoli FA: Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. Cancer Res 2000, 60:2562-2566.

32. Wernert N, Locherbach C, Wellmann A, Behrens P, Hügel A: Presence of genetic alterations in microdissected stroma of human colon and breast cancers. J Mol Med 2000, 78:B30.

33. Qiu W, Hu M, Sridhar A, Opeskin K, Fox S, Shipitsin M, Triveri M, Thompson ER, Ramakrishna M, Gorringe KL, Polyak K, Haviv I, Campbell IG: No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet 2008, 40:650-655.

34. Dumont P, Leu JL, Della Pietra AC, 3rd, George DL, Murphy M: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003, 33:357-365.

35. Sullivan A, Syed N, Gasco M, Bergamaschi D, Trigante G, Attard M, Hiller L, Farrell PJ, Smith P, Lu X, Crock T: Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 2004, 23:3328-3337.

36. Park DJ, Zhang W, Stoehlmacher J, Tao-Wei D, Groshen S, Gil J, Yun J, Sones E, Mallick N, Lenz HJ: ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol 2003, 1:162-166.

37. Arva NC, Gopen TR, Talbot KE, Campbell LE, Chicas A, White DE, Bond GL, Levine AJ, Bargonetti J: A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem 2005, 280:26776-26787.

38. Weaver VM, Leilievre S, Lakins JN, Chrenek MA, Jones JC, Giancotti F, Werb Z, Bissell MJ: Beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2002, 2:205-216.

39. Sethi T, Rintoul RC, Moore SM, MacKinnon AC, Salter D, Choo C, Chilvers ER, Dransfield I, Donnelly SC, Strieter R, Haslett C: Extra-cellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 1999, 5:662-668.

40. Sadlonova A, Novak Z, Johnsson MR, Bowe DB, Gault SR, Page GP, Thottassery JV, Welch DR, Frost AR: Breast fibroblasts modulate epithelial cell proliferation in three-dimensional in vitro coculture. Breast Cancer Res 2005, 7:R46-59.

41. Kerr DJ, Wheldon TE, Kerr AM, Kaye SB: In vitro chemosensitivity testing using the multicellular tumor spheroid model. Cancer Drug Deliv 1987, 4:63-74.

42. Zhang X, Wang W, Yu W, Xie Y, Zhang X, Zhang Y, Ma X: Development of an in vitro multicellular tumor spheroid model using microencapsulation and its application in anticancer drug screening and testing. Biotechnol Prog 2005, 21:1289-1296.

43. Barding B, Hofmann HS, Silber RE, Simm A: Differential impact of fibroblasts on the efficient cell death of lung cancer cells induced by paclitaxel and cisplatin. Cancer Biol Ther 2008, 7(8):1250-1261.

44. Morin PJ: Drug resistance and the microenvironment: nature and nurture. Drug Resit Updat 2003, 6:169-172.

Pre-publication history
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2407/8/364/prepub

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

Publish with BioMed Central and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK

Your research papers will be:
• available free of charge to the entire biomedical community
• peer reviewed and published immediately upon acceptance
• cited in PubMed and archived on PubMed Central
• yours — you keep the copyright